DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Prostate Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Metastatic Prostate Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Metastatic Prostate Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Metastatic Prostate Cancer: An Overview
Metastatic Prostate Cancer (MPC) is a type of prostate cancer that spreads to the other parts of the body, i.e., cancer has “metastasized.” Most often, prostate cancer spreads to the bones or lymph nodes. It’s also common for it to spread to the liver or lungs. It’s rarer for it to move to other organs, such as the brain. Metastatic prostate cancer is an advanced form of cancer. There’s no cure, but it can treat it and control it. Most men with advanced prostate cancer live a normal life for many years.
About 80 percent of the time prostate cancer cells metastasize or spread, they get spread to bones, such as the hip, spine, and pelvis bones. It can be by direct invasion or by traveling through your blood or lymphatic system. Metastatic prostate cancer is considered advanced prostate cancer. Once relocated, the cells begin to grow and form new tumors. This new growth is still classified as prostate cancer because the cancer first developed in the prostate.
Metastatic Prostate Cancer Market Key Facts
-
The total market size in the 7MM for metastatic castration-resistant prostate cancer (mCRPC) was estimated to be nearly USD 6,400 million in 2022, which is expected to show positive growth by 2032.
-
Among the EU4 countries, Germany captured the maximum market share in 2022, whereas Spain was at the bottom of the ladder in the same year in metastatic prostate cancer setting.
-
The market size of mCSPC in Japan in 2022 was around USD 190 million, which is expected to increase during the study period (2019–2032).
-
As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 7,900,000 cases in 2022. These cases are projected to increase during the study period, i.e., 2019–2032.
-
The United States had the highest number of diagnosed prostate cancer cases in 2022, with approximately 1,460,000 reported cases.
-
In 2022, total cases of metastatic CSPC/HSPC and metastatic CRPC were around 100,000 and 120,000, respectively, in the 7MM. These cases are expected to increase by 2032.
-
In the US, the total diagnosed prevalent cases of prostate cancer by clinical stages were highest in locally advanced (Stage I–III), accounting for over 800,000 cases, followed by biochemical recurrence/progressive and metastatic cases, respectively, in 2022.
-
Among the EU4, Germany accounted for the highest number of prevalent metastatic prostate cancer cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
-
The total number of diagnosed prevalent cases of prostate cancer in Japan was ~ 270,000 in 2022 and is expected to increase during the forecast period.
Metastatic Prostate Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Metastatic Prostate Cancer pipeline therapies. It also thoroughly assesses the Metastatic Prostate Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Metastatic Prostate Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Metastatic Prostate Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Metastatic Prostate Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Metastatic Prostate Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Metastatic Prostate Cancer Epidemiology, Segmented as –
-
Total prevalent cases of prostate cancer
-
Total diagnosed cases of prostate cancer
-
Age-specific cases of prostate cancer
-
Total diagnosed cases of prostate cancer by clinical stages
-
Total metastatic cases of prostate cancer
-
Total treated cases of mCRPC
-
Total treated cases of mCSPC
Metastatic Prostate Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Metastatic Prostate Cancer market or expected to be launched during the study period. The analysis covers the Metastatic Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Metastatic Prostate Cancer drugs based on their sale and market share.
The report also covers the Metastatic Prostate Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Metastatic Prostate Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Metastatic Prostate Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-market
Metastatic Prostate Cancer Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Metastatic Prostate Cancer. Currently, Foresee Pharmaceuticals and Myovant Biosciences is leading the therapeutics market with its Metastatic Prostate Cancer drug candidates in the most advanced stage of clinical development.
Metastatic Prostate Cancer Companies Actively Working in the Therapeutics Market Include
AB Science, Abbvie, Advanced Accelerator Applications (A Novartis Company), Advaxis, Amgen, , Antigen Express, Aptevo Therapeutics, Arcus Biosciences, Arvinas Inc., Astellas Pharma Inc, Astellas Pharmaceuticals, AstraZeneca plc, Bavarian Nordic, Bayer, Beigene, BioNTech SE, Boehringer Ingelheim, Bristol Myers Squibb, Cancer Targeted Technology, Celgene, CellCentric, Cleveland BioLabs, Constellation Pharmaceuticals, Corcept Therapeutics, DexTech Medical, Effector Therapeutics, Eli Lilly and Company, Epizyme Inc., ESSA Pharma, Five Eleven Pharma, Foresee Pharmaceuticals, Fortis Therapeutics, Genentech, Genzada Pharmaceuticals, Gilead, Harpoon Therapeutics, Hinova Pharmaceuticals USA, Inc., Immunomedics, Inhibitor Therapeutics, Inc., Innocrin Pharmaceutical, Inovio Pharmaceuticals, Janssen Research & Development, LLC, Jiangsu HengRui Medicine Co., Ltd., Kangpu Biopharmaceuticals, Karyopharm Therapeutics, Laekna Therapeutics Shanghai Co. Ltd., Madison Vaccines, Inc, MedImmune, Medivation, Merck Sharp & Dohme Corp., Minneamrita Therapeutics, Modra Pharmaceuticals, Myovant Biosciences, Nektar Therapeutics, Nerviano Medical Sciences, NewLink Genetics, Novartis, Oncology Venture, OncoMax, OPKO Renal/Vifor Fresenius, ORIC Pharmaceuticals, Orion Corporation, Orion Pharma, Pfizer Inc., Poseida Therapeutics, Progenics Pharmaceuticals, Inc., Regeneron Pharmaceuticals/Sanofi, Roche, SeleXel, Sotio, Suzhou Kintor Pharmaceutical, Taiho Pharmaceutical, Telix Pharmaceuticals, Tesaro, Tmunity Therapeutics, Tracon, Trovagene, Ultimovacs ASA, Vaccitech, ValiRx, VasGene Therapeutics, Veru Inc., WntResearch, Zenith Epigenetics, and others.
Emerging and Marketed Metastatic Prostate Cancer Therapies Covered in the Report Include:
-
FP-001: Foresee Pharmaceuticals
-
Relugolix: Myovant Biosciences
-
Atezolizumab: Genentech
-
Darolutamide: Bayer
-
DCVAC/PCa: Sotio
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Prostate Cancer Competitive Intelligence Analysis
4. Metastatic Prostate Cancer Market Overview at a Glance
5. Metastatic Prostate Cancer Disease Background and Overview
6. Metastatic Prostate Cancer Patient Journey
7. Metastatic Prostate Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Metastatic Prostate Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Prostate Cancer Unmet Needs
10. Key Endpoints of Metastatic Prostate Cancer Treatment
11. Metastatic Prostate Cancer Marketed Therapies
12. Metastatic Prostate Cancer Emerging Drugs and Latest Therapeutic Advances
13. Metastatic Prostate Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Prostate Cancer Market Outlook (In US, EU5, and Japan)
16. Metastatic Prostate Cancer Companies Active in the Market
17. Metastatic Prostate Cancer Access and Reimbursement Overview
18. KOL Views on the Metastatic Prostate Cancer Market
19. Metastatic Prostate Cancer Market Drivers
20. Metastatic Prostate Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Paraganglioma Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Paraganglioma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Paraganglioma market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research